Carlos Antônio da Silva Franca

The seven-year preliminary results of brachytherapy with Iodine-125 seeds for localized prostate cancer treated at a Brazilian single-center

OBJECTIVE To report the seven-year preliminary results of a single-center on brachytherapy with Iodine-125 seeds, used in combination with external beam radiotherapy in selected patients with localized prostate cancer (T1-T2). MATERIALS AND METHODS All 105 patients treated by brachytherapy with Iodine-125 seeds, from January/1998 to December/2004, were retrospectively analyzed. The prescribed dose was 144 Gy at the periphery of the prostate for isolated brachytherapy, and 110 Gy for the combination with external beam radiotherapy. The external beam radiotherapy dose was 45 Gy, at the prostatic bed. Neoadjuvant hormone therapy was indicated for selected patients, who received luteinizing hormone-releasing hormone (LH-RH) and/or antiandrogens. For definition of biochemical relapse, it was adopted the American Society for Therapeutic Radiology and Oncology consensus. RESULTS Of the 105 patients treated, 90 were followed for a mean period of 70 months. Biochemical disease control was achieved in 62 (69%) and biochemical recurrence was manifested in 28 (31%). The analysis of each risk group showed biochemical disease control rates of 79%, 71% and 52% in the low, intermediate and high risk groups, respectively. The mean time for biochemical recurrence was 22 months. Genitourinary acute toxicity was classified as grade 0-2 (RTOG) in 88.5% and in 94.2% for the late toxicity (RTOG/EORTC). Gastrointestinal acute toxicity was graded as 0-2 (RTOG) in 100% and in 97.7% for the late morbidity. No grade 5 was detected. CONCLUSIONS Brachytherapy with Iodine-125 seeds is an effective alternative treatment for early stage prostatic cancer, with good biochemical disease control rates and low to moderate toxicity. The best results were obtained in low and intermediate risk patients.

Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherapy

Objective To evaluate the relationship between two year PSA nadir (PSAn) after brachytherapy and biochemical recurrence rates in prostate cancer patients. Materials and Methods In the period from January 1998 to August 2007, 120 patients were treated with iodine-125 brachytherapy alone. The results analysis was based on the definition of biochemical recurrence according to the Phoenix Consensus. Results Biochemical control was observed in 86 patients (71.7%), and biochemical recurrence, in 34 (28.3%). Mean PSAn was 0.53 ng/ml. The mean follow-up was 98 months. The patients were divided into two groups: group 1, with two year PSAn < 0.5 ng/ml after brachytherapy (74 patients; 61.7%), and group 2, with two year PSAn ≥ 0.5 ng/ml after brachytherapy (46 patients; 38.3%). Group 1 presented biochemical recurrence in 15 patients (20.3%), and group 2, in 19 patients (43.2%) (p < 0.02). The analysis of biochemical disease-free survival at seven years, stratified by the two groups, showed values of 80% and 64% (p < 0.02), respectively. Conclusion Levels of two year PSAn ≥ 0.5 ng/ml after brachytherapy are strongly correlated with a poor prognosis. This fact may help to identify patients at risk for disease recurrence.Objective To evaluate the relationship between two year PSA nadir (PSAn) after brachytherapy and biochemical recurrence rates in prostate cancer patients. Materials and Methods In the period from January 1998 to August 2007, 120 patients were treated with iodine-125 brachytherapy alone. The results analysis was based on the definition of biochemical recurrence according to the Phoenix Consensus. Results Biochemical control was observed in 86 patients (71.7%), and biochemical recurrence, in 34 (28.3%). Mean PSAn was 0.53 ng/ml. The mean follow-up was 98 months. The patients were divided into two groups: group 1, with two year PSAn < 0.5 ng/ml after brachytherapy (74 patients; 61.7%), and group 2, with two year PSAn ≥ 0.5 ng/ml after brachytherapy (46 patients; 38.3%). Group 1 presented biochemical recurrence in 15 patients (20.3%), and group 2, in 19 patients (43.2%) (p < 0.02). The analysis of biochemical disease-free survival at seven years, stratified by the two groups, showed values of 80% and 64% (p < 0.02), respectively. Conclusion Levels of two year PSAn ≥ 0.5 ng/ml after brachytherapy are strongly correlated with a poor prognosis. This fact may help to identify patients at risk for disease recurrence.

Effects of supplementation of antioxidant vitamins and lipid peroxidation in critically ill patients

INTRODUCTION Critical patients present systemic inflammatory process that can be followed by decrease in plasma concentrations of antioxidant vitamins. OBJECTIVE [corrected] The aim of this study was to evaluate the effect of the supplementation of antioxidant vitamins in critical patients and their relation with lipid peroxidation. METHODS 23 patients went on a standard diet (G1) and 11 went on a diet with daily supplementation of 10,000 IU of vitamin A, 400 mg of vitamin E and 600 mg of vitamin C (G2). The APACHE II score was made. Serum concentrations of retinol, β-carotene, vitamins C and E, malondialdehyde (MDA) and C-reactive protein was measured before (T0) and on the 8th day after the beginning of the nutritional therapy (T1). The groups had been monitored on T0, T1 and T2, (at discharges or death) on the following parameters: mechanical ventilation; hospitalization days; mortality; infection incidence. RESULTS Serum concentrations of MDA and vitamin E were significantly lower in G2 after intervention and strong tendency to increase vitamin C. There were not significant differences between the groups regarding the clinical parameters. CONCLUSIONS The doses of vitamin A, C and E that were indicated were effective for the current lipid peroxidation reduction.

Radioactive seed migration after prostate brachytherapy with iodine-125 using loose seeds versus stranded seeds.

OBJECTIVES To assess the incidence and clinical parameters that could influence migration of seeds in localized prostate cancer patients treated by stranded versus loose sources by Iodine-125 brachytherapy. MATERIALS AND METHODS 100 patients were treated from January/1998 until December/2006. Age, PSA, clinical stage, Gleason, prostate volume, number of seeds, activity of radioactive seeds, and dosimetric parameters, such as V100, V150 and D90 were evaluated. RESULTS Mean follow-up was 79 months (18 - 120. CI 95%: 72 - 85). Overall, 6 of 100 patients experienced seed migration. Seed migration was found in 4/50 (8%) patients using loose seeds and in 2/50 (4%) treated by stranded seeds. Mean value dosimetric parameters for stranded seeds were greater than those for loose seeds (V100(%): 88.7/82, D90(Gy): 149.2/140.3, D90(%): 104.2/93.8, V150 (%): 53.8/47, respectively). No significant difference in migration of seeds was detected between loose and stranded seeds considering age (p = 0.33), PSA (p = 0.391), prostate volume (p = 0.397), activity of radioactive seeds (p = 0.109), number of seeds (p = 0.338), V100 (p = 0.332), although significant differences were measured in the values of D90(% and Gy) (p = 0.022 and 0.011) and V150 (p = 0.023). CONCLUSIONS Seed migration after brachytherapy might occur and it does affect post-implant dosimetry.

The relationship between serum vitamin A and breast cancer staging before and after radiotherapy

INTRODUCTION Several adverse effects of radiotherapy have been associated with the process of increased oxidative stress in the organism. In this context, vitamin A noteworthy for its important role in combating oxidative stress, in addition to its chemoprotective effect. OBJECTIVE To assess the serum levels of vitamin A (retinol and β-carotene) and their relationship to breast cancer staging in patients before and after radiotherapy. METHODS This is a prospective study of women with breast cancer who were evaluated from October 2011 to September 2012 before (T0) and after radiotherapy (T1-7 days). Serum retinol and β-carotene levels were analyzed using High Performance Liquid Chromatography. The assignment of breast cancer stages was based on the classification of malignant tumors that has been proposed by the International Union Against Cancer. RESULTS 230 patients (mean age 63.6 years, SD ± 9.38) were evaluated. There was a significant reduction in the serum retinol (45.1 ± 18.2 μg/dL at T0 to 27.1 ± 11.7 μg/dL at T1, p < 0.001) and β-carotene (209.0 ± 153.6 μg/L at T0 to 47.7 ± 25.5 μg/L at T1, p < 0.001). There was also a significant difference in serum retinol (p < 0.001) and β-carotene (p = 0.003) levels based on the disease stage. CONCLUSIONS It is recommended the early establishment of adequation serum concentrations of retinol and beta-carotene, offering nutritional assistance for those patients with deficiencies, in order to minimize the harmful effects of radiation.